Patents by Inventor Shalley K. Gupta
Shalley K. Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7485432Abstract: Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.Type: GrantFiled: February 27, 2004Date of Patent: February 3, 2009Assignee: 3M Innovative Properties CompanyInventors: Jason R. Fink, Keith B. Gorden, Kevin S. Gorski, Shalley K. Gupta, Xiaohong Qiu, John P. Vasilakos
-
Publication number: 20040197865Abstract: The present invention provides gene expression systems useful for detecting agonists of Toll-like receptors. The gene expression systems include a nucleic acid sequence encoding a Toll-like receptor and a second nucleic acid sequence that encodes a reporter operably linked to an expression control sequence. The recombinant cell lines include a gene expression system according to the present invention.Type: ApplicationFiled: December 10, 2003Publication date: October 7, 2004Applicant: 3M Innovative Properties CompanyInventors: Shalley K. Gupta, Tarun K. Ghosh, Jason R. Fink
-
Publication number: 20040191833Abstract: Methods of identifying compounds that selectively modulate cellular activities mediated by a common TLR are provided. Generally, the methods include providing an assay to detect modulation of a first cellular activity mediated by a TLR; providing an assay to detect modulation of a second cellular activity mediated by the TLR; performing each assay using a test compound; and identifying the test compound as a compound that selectively modulates at least one cellular activity of a plurality of activities mediated by a common TLR if the test compound modulates the first cellular activity to a different extent than it modulates the second TLR-mediated cellular activity. Compounds identified by such methods, pharmaceutical compositions including such compounds, and methods of treating a condition by administering such pharmaceutical compositions to a subject are also provided.Type: ApplicationFiled: March 24, 2004Publication date: September 30, 2004Applicant: 3M Innovative Properties CompanyInventors: Jason R. Fink, Shalley K. Gupta
-
Publication number: 20040171086Abstract: Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.Type: ApplicationFiled: February 27, 2004Publication date: September 2, 2004Applicant: 3M Innovative Properties CompanyInventors: Jason R. Fink, Keith B. Gorden, Kevin S. Gorski, Shalley K. Gupta, Xiaohong Qiu, John P. Vasilakos
-
Publication number: 20040147543Abstract: Aryl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.Type: ApplicationFiled: December 18, 2003Publication date: July 29, 2004Applicant: 3M Innovative Properties CompanyInventors: David S. Hays, Shri Niwas, Tushar Kshirsagar, Tarun K. Ghosh, Shalley K. Gupta, Phillip D. Heppner, Bryon A. Merrill, Jason D. Bonk, Michael E. Danielson, John F. Gerster, Chad A. Haraldson, Sarah Johannessen, Maureen A. Kavanagh, Kyle J. Lindstrom, Ryan B. Prince, Matthew R. Radmer, Michael J. Rice, David J. Squire, Sarah A. Strong, Joshua R. Wurst
-
Publication number: 20040132079Abstract: The present invention provides assays useful for detecting agonists of Toll-like receptors. The assays include, generally, providing a cell culture transfected with a nucleic acid sequence that encodes a reporter operably linked to a TLR-inducible expression control sequence; contacting the cell culture with a test compound; and identifying the compound as a TLR agonist if TLR-inducible expression of the reporter can be detected.Type: ApplicationFiled: December 10, 2003Publication date: July 8, 2004Applicant: 3M Innovative Properties CompanyInventors: Shalley K. Gupta, Tarun K. Ghosh, Jason R. Fink
-
Publication number: 20020107195Abstract: CXCR4 and SDF-1&agr; polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CXCR4 and SDF-1&agr; polypeptides and polynucleotides in the design of protocols for the treatment of inflammatory diseases, angiogenic diseases, and infections, such Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: September 17, 2001Publication date: August 8, 2002Applicant: SmithKline Beecham CorporationInventor: Shalley K. Gupta
-
Publication number: 20020107196Abstract: CXCR4 and SDF-1&agr; polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CXCR4 and SDF-1&agr; polypeptides and polynucleotides in the design of protocols for the treatment of inflammatory diseases, angiogenic diseases, and infections, such Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: September 17, 2001Publication date: August 8, 2002Applicant: SmithKline Beecham CorporationInventor: Shalley K. Gupta
-
Patent number: 5935928Abstract: The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.Type: GrantFiled: February 14, 1996Date of Patent: August 10, 1999Assignee: Eli Lilly and CompanyInventors: Shalley K. Gupta, Jai Pal Singh
-
Patent number: 5538949Abstract: The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.Type: GrantFiled: May 11, 1995Date of Patent: July 23, 1996Assignee: Eli Lilly and CompanyInventors: Shalley K. Gupta, Jai P. Singh
-
Patent number: 5512550Abstract: The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.Type: GrantFiled: May 11, 1995Date of Patent: April 30, 1996Assignee: Eli Lilly and CompanyInventors: Shalley K. Gupta, Jai P. Singh